Entering text into the input field will update the search result below

Morphosys settles patent dispute with Janssen and Genmab

Feb. 01, 2019 3:24 PM ETMorphoSys AG (MOR) StockBy: Douglas W. House, SA News Editor
  • MorphoSys (NASDAQ:MOR +1.3%), Johnson & Johnson's (JNJ +0.7%) Janssen Biotech and Genmab A/S (GMXAY) have settled their patent infringement dispute related to daratumumab, a CD38-directed monoclonal antibody for the treatment of multiple myeloma marketed under the brand name Darzalex, that Janssen and Genmab collaborated on under a 2012 agreement.
  • MorphoSys filed litigation in 2016 against the two companies accusing them of infringing on its U.S. Patent No. 8,263,746. Two other patents were added later. Janssen and Genmab subsequently filed counterclaims.
  • Additional details are not disclosed.

Recommended For You

More Trending News

About MOR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MOR--
MorphoSys AG